Monthly Archives: March 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Crown Media Holdings Inc. of an Investigation Concerning the Fairness of the Sale of the Company to Hallmark — CRWN

NEW YORK, NY / ACCESSWIRE / March 9, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Crown Media Holdings Inc. (NASDAQ: CRWN) stock prior to March 9, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Crown Media Holdings Inc. to Hallmark for $5.05 in cash per share. Hallmark Cards, Incorporated and its affiliates own more than 90% of Crown Media’s outstanding stock. To learn more about the action and your rights, go to:

http://zlk.9nl.com/crown-media-holdings-crwn

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 437668

Kaizen Announces the Passing of James Spooner, Increase of Non-brokered Private Placement and Update on Activities

VANCOUVER, BC / ACCESSWIRE / March 9, 2016 / Kaizen Capital Corp. (TSXV: KZN.H) (the “Corporation” or “Kaizen“) announces that it has been advised of the passing of James Spooner on February 25, 2016.

Mr. Spooner was recently appointed as VP of Finance for Kaizen in anticipation of the closing of the on going acquisition of the Mackie property in British Columbia. The Company extends its sincere condolences to Mr. Spooner’s family during this very difficult time.

The Corporation also reports that the previously announced non-brokered private placement (February 18, 2016) of convertible securities comprised of subscription receipts in Kaizen (the “Subscription Receipts“) for CDN$1,130,000 at an issue price of $0.10 per Subscription Receipt has been increased to a maximum of CDN$1,188,000 (the “Kaizen Financing“). Each Subscription Receipt will be convertible into Kaizen Shares on a one for one basis upon completion of the Corporation’s proposed Qualifying Transaction as such term is defined in the policies of the TSX Venture Exchange. In certain instances, the Corporation may pay finder’s fees to certain registrants or eligible persons exempt from registration on a portion of the Kaizen Financing. Proceeds of the Kaizen Financing will be held in escrow pending closing of the Qualifying Transaction. The net proceeds of the Kaizen Financing will be used: (a) to fund the business plan of Kaizen; (b) for Qualifying Transaction expenses; and (c) for general working capital purposes.

A definitive agreement to acquire the Mackie Project in northwestern British Columbia (January 14, 2016) is nearly complete and Kaizen is continuing to work on completing the required documents required to close the Qualifying Transaction.

Kaizen was incorporated under the laws of Alberta and has a head office in Vancouver, British Columbia. It is a “capital pool company” under the policies of the TSX Venture Exchange (the “Exchange“) and is a reporting issuer in the provinces of British Columbia, Alberta and Ontario. It is intended that the Qualifying Transaction will constitute a “Qualifying Transaction” of the Corporation, as such term is defined in the policies of the Exchange.

The Qualifying Transaction will be carried out by parties dealing at arm’s length to one another and therefore will not be considered to be a “Non-Arm’s Length Qualifying Transaction”, as such term is defined under the policies of the Exchange.

For Further Information, Please Contact:

Kaizen Capital Corp.
Richard Graham, Director
Telephone: (604) 689-1428

Cautionary Statements

This press release contains “forward-looking information” within the meaning of applicable securities laws relating to the proposal to complete the Qualifying Transaction and associated transactions, including statements regarding the terms and conditions of the Qualifying Transaction, the Options, the Kaizen Financing, and the use of proceeds of the Kaizen Financing. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the parties will not proceed with the Qualifying Transaction, the Kaizen Financing and associated transactions, that the ultimate terms of the Qualifying Transaction, the Kaizen Financing and associated transactions will differ from those that currently are contemplated, and that the Qualifying Transaction, the Kaizen Financing and associated transactions will not be successfully completed for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities). The statements in this press release are made as of the date of this release. The Corporation undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Corporation, Tudor, their securities, or their respective financial or operating results or (as applicable).

Completion of the Kaizen Financing is subject to regulatory approvals.

Completion of the Qualifying Transaction is subject to a number of conditions including, but not limited to, Exchange acceptance and, if required by the Exchange policies, majority of the minority shareholder approval. Where applicable, the Qualifying Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Qualifying Transaction will be completed as proposed or at all.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Qualifying Transaction and has neither approved or disapproved the contents of this press release.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

The common shares have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

SOURCE: Kaizen Capital Corp.

ReleaseID: 437666

Clinical Trials of Melanoma Market Global Review H1 2016

ReportsnReports adds Melanoma Market research to its database.

Clinical Trials of Melanoma Market Global Review H1 2016

Pune, India – March 9, 2016 /MarketersMedia/

This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Get discount on this research report at http://www.reportsnreports.com/contacts/Discount.aspx?name=504672 .

Companies discussed in this research are:-

• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• AstraZeneca Plc
• Pfizer Inc.
• Ludwig Institute For Cancer Research Ltd
• Eisai Co., Ltd.
• Amgen Inc.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete research report of 1403 is available at http://www.reportsnreports.com/reports/504672-melanoma-global-clinical-trials-review-h1-2016.html .

Reasons to buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

For more information about us, please visit http://www.reportsnreports.com/

Contact Info:
Name: Ritesh Tiwari
Organization: ReportsandReports
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41

Source: http://marketersmedia.com/clinical-trials-of-melanoma-market-global-review-h1-2016/106191

Release ID: 106191

Investor Calendar Invites You to the Nortech Systems Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Thursday, March 10, 2016

MINNEAPOLIS, MN / ACCESSWIRE / March 9, 2016 / Nortech Systems Incorporated (NASDAQ: NSYS) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Thursday, March 10, 2016 at 11:00 AM Eastern Time.

To participate in this event, dial 877-407-8031 domestically, or 201-689-8031 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174731 as well as via the Nortech website (www.nortechsys.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.nortechsys.com.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID # 13630938. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on March 24, 2016.

About Nortech Systems Incorporated

Nortech Systems Incorporated (www.nortechsys.com), based in Maple Grove, Minn., is a full-service electronics manufacturing services (EMS) provider of wire and cable assemblies, printed circuit board assemblies and higher-level complete box build assemblies for a wide range of industries. Markets served include industrial equipment, aerospace/defense and medical. The company has manufacturing capabilities in the U.S. and Latin America. Nortech Systems, Inc. is traded on the NASDAQ Stock Market under the symbol NSYS.

SOURCE: Investor Calendar

ReleaseID: 437662

Investor Calendar Invites You to the Dynamic Materials Fourth Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, March 10, 2016

BOULDER, CO / ACCESSWIRE / March 9, 2016 / Dynamic Materials Corporation (NASDAQ: BOOM) will host a conference call and live webcast to discuss the results of the fourth quarter 2015, to be held Thursday March 10, 2016 at 5:00 PM Eastern Time.

To participate in this event, dial 877-407-0778 domestically, or 201-689-8565 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174730 as well as via the Dynamic Materials website (www.dmcglobal.com/investors).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.dmcglobal.com/investors.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID # 13630868. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on March 17, 2016.

About Dynamic Materials Corporation

Based in Boulder, Colorado, DMC operates in two sectors: industrial infrastructure and oilfield products and services. The industrial infrastructure sector is served by DMC’s NobelClad business, the world’s largest manufacturer of explosion-welded clad metal plates, which are used to fabricate capital equipment utilized within various process industries and other industrial sectors. The oilfield products and services sector is served by DynaEnergetics, an international developer, manufacturer and marketer of advanced explosive components and systems used to perforate oil and gas wells. For more information, visit the Company’s website at: http://www.dmcglobal.com.

SOURCE: Investor Calendar

ReleaseID: 437660

Investor Calendar Invites You to the Cantel Medical Corp. Second Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, March 10, 2016

LITTLE FALLS, NJ / ACCESSWIRE / March 9, 2016 / Cantel Medical Corp. (NYSE: CMN) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Thursday, March 10, 2016 at 11:00 AM Eastern Time.

To participate in this event, dial 877-407-8033 domestically approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174750 as well as via the Cantel website (www.cantelmedical.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.cantelmedical.com.

You may access the teleconference replay by dialing 877-660-6853, referencing conference ID # 13631451. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on May 10, 2016.

About Cantel Medical Corp.

Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products. For further information, visit the Cantel website at www.cantelmedical.com.

SOURCE: Investor Calendar

ReleaseID: 437661

Investor Calendar Invites You to the Provectus Biopharmaceuticals Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Thursday, March 10, 2016

KNOXVILLE, TN / ACCESSWIRE / March 9, 2016 / Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Thursday, March 10, 2016 at 4:00 PM Eastern Time.

To participate in this event, dial 877-407-4019 domestically, or 201-689-8337 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event onlineat www.investorcalendar.com/IC/CEPage.asp?ID=174725 as well as via the Provectus Biopharmaceuticals website (www.pvct.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.pvct.com.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID # 13629346. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on June 30, 2016.

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

SOURCE: Investor Calendar

ReleaseID: 437664

Abs after 40 Reviewed by Healthy Nutrition – Techniques and Training for Six Pack Abs

NEW YORK, NY / ACCCESSWIRE / March 9, 2016 / Mark Mcilyar introduces a totally new approach in “Abs after 40” to build up a muscular body with abs by following a simple workout plan at home. Abs after 40 contains important tips by one of the best fitness experts in the industry. This Report Uncovers Important Aspects of Abs after 40

This news report by Mark Simone caters latest information about Mark Mcilyar’s Abs after 40 system consumers must know. “Abs after 40” is a newly released fitness program by Mark Mcilyar, a 53 year old fitness trainer and expert who has spent all his life in discovering fitness secrets for a muscular and toned body. Abs after 40 helps improve a person’s core strength. Mark Mcilyar teaches men over 40 to balance hormonal changes, reduce fat, burn calories and build up muscles with ideal abs.

Mark Simone from Healthy Nutrition reports his latest findings on Abs after 40

According to Mark, This program is designed for men of the age where they are short of time and couldn’t pay much heed to their fitness, resulting in prominent appearance of aging, weak looking body, wrinkles, lack of energy and confidence. Mark suggests that it is very important for people to take out at least 15 minutes daily from their busy routine for exercising to maintain fitness. Abs after 40 considered to be a good help for men who doesn’t want to lose their younger looking body due to aging and wants to maintain a muscular and toned body.

Mark further states, “The fitness tips and tricks in the program are subjected to work in a way that it maximizes the chances of positive and long time results. There are simple 5 minutes’ exercising tips for every part of the body including arms, belly, hips and thighs; each tip is about the movements that can help great in draining out excessive fat and strengthening the muscles for tighter and toned shape.”

Access The News Report by Mark Simone Exposing The
Breakthrough Ab Training Method by
Mark
Mcilyar

Abs after 40 has a vast collection of different types of exercises, from light movements to major, affecting their respective area of the body which are targeted to kill fats. Mark recommends that men should do these exercises on daily basis along with the intake of some juice that will energize the body so that it performs the workout plan properly. This training plan intends to build up muscles and abs without doing constant overlong exercises in gym, strict diets and tough exercises, instead it has turned the conventional form of tough workout plans in to simple fitness strategies that can be done by any man of any age.

He further adds, “The plan works on two approaches, one is to attain fitness through workouts and the other is to work on the inside of the body by balancing hormones which cause the early aging and weakness on man’s body. According to research, the clutter in the Testosterone production of the body may become the reason of the gradual dullness in the body. Men with low testosterone level might notice a drastic change in the muscles and energy of the body.”

Abs after 40 has revealed ways to balance testosterone production in the body naturally with the help of some juices and early morning one minute meditation technique that is already being set up for the ease of people in the program. Mark explained why the bodies of young guys aged 20 to 30 attain and retain six packs and abs easily, it is because of the perfect balance of testosterone hormone in the body and as the age grows, the testosterone formation keeps reducing, resulting in the clear sign of aging such as weak muscles, bulging tummy and double chin. The program contains a list of food ingredients with natural abilities to boost testosterone production and stop hormonal changes, keeping the body looking young even after age 40.

The improvement in testosterone production not only improves a man’s physique and looks but also plays a vital role in improving sex life as it boost up sex drive of men and increases sexual power. Simple movements and easy-to-make juices can help men control their hormonal imbalance and prevent its consequences. Abs after 40 contains all such information along with some quick tips to make it all happen and deliver results in few days.

The plan is solely designed for men over 40 age to fix the imbalance of Testosterone in the body with the help of Mark’s secret workout tips and suggestion that will provide positive results in the form of an in-shape, toned and muscular body. The program contains three phases named Fat Loss Jump-start, Full-Auto Fat Burning Mode and Male Hormone Optimization. These phases work step-by step to drive a body through the whole process of fat burning properly.

To Visit The Official Website of Abs after 40 Program By Mark Mcilyar Click Here

Each workout contains a blend of in-home cardio and resistance training movements that don’t needed to be done in gym or at any fitness training center. Abs after 40 is destined to increase energy, toned body, balance hormones, fast weight loss, improved strength and an overall improvement in the physique and health. For this purpose, the program has added workout tips, fitness strategies, Mark’s training, a list of useful food items and recipes.

To conclude his review, Mark states, “Abs after 40 is the only fitness training program of its kind which targets men over 40 in their fitness lacking and help them to improve it. It has the power to grant an older man a body of a younger 25 year old man, simply by just following the Mark’s program well. The program is now available worldwide on its official website in a discounted offer of only $97 for a time being. They also offer 60 days money refund facility under some conditions that can be checked from its website or from a call to their customer service center.” Local 512-201-4646, Email Support@GetAbsAfter40.com.

About Healthy Nutrition

Healthy Nutrition is an independently owned company situated in New York, NY that assists consumers to find user-based information on specified products and services to help individuals determine if those specific products and services are in fact a suitable fit for them.

CONTACT INFORMATION

Mark Simone
Healthy Nutrition
Mark@healthynutritions.co

SOURCE: Healthy Nutrition

ReleaseID: 437659

Michael Moore, Honda of Fife, Earns Distinction in Honda’s Recognition Program

Michael Moore has achieved membership in the Council of Sales Leadership for the first time; he has been serving the needs of customers for 3 years at Honda of Fife.

Michael Moore, Honda of Fife, Earns Distinction in Honda’s Recognition Program

Tacoma, WA, USA – March 9, 2016 /PressCable/

Fife, WA, March 8th, 2016 ‒ Honda of Fife, at 4301 20th St E, announced that Michael Moore has been honored by American Honda Motor Co., Inc., with Silver membership in the prestigious Honda Council of Sales Leadership. This highly respected designation is reserved for Honda top performers who consistently surpass customer expectations and program benchmarks of success.

The Council of Sales Leadership program is a yearlong recognition initiative promoting excellence in sales achievement, customer satisfaction, and professional development. While more than 15,000 Honda sales consultants participated nationwide, only 22 percent attained membership status.

Michael Moore has achieved membership in the Council of Sales Leadership for the first time; he has been serving the needs of customers for 3 years at Honda of Fife. Earning membership in the Council of Sales Leadership (COSL) is an elite achievement that bestows honor on both the Sales Consultant and his or her dealership.

“Michael Moore displays exactly what we stand for at Honda of Fife…Customer Satisfaction. We’re especially proud of Michael Moore for that. He’s a very deserving award winner.”

Michael has many 5 star reviews written online about him by customers but it is a great honor to be awarded by the company itself.

DealerRater review for Michael

“We are very pleased with the Sales Dept. & Finance staff. They were very professional, courteous and indeed committed to customer satisfaction, without high pressure. Michael Moore and the Sales manager were outstanding. Thank you !”

More information about Honda of Fife and Michael Moore visit www.hondaoffife.com Honda of Fife is the most “Liked” Honda dealership in WA. They are committed to customer satisfaction and work hard to make the car buying experience easy. Honda of Fife is family owned and cares about the local community. Honda of Fife can help with a vehicle purchase or help maintain vehicle service.

Honda of Fife was voted the #1 Honda dealership in WA state of franchise dealerships in 2014 and 2015 by the Best of Western WA King5.

For more information about us, please visit http://www.hondaoffife.com

Contact Info:
Name: Michael Moore
Organization: Honda of Fife
Address: 4301 20th St E
Phone: 253-922-2673

Release ID: 106404

B. Riley & Co. Reiterates Buy Rating of Sysorex Global

NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Market Exclusive announces that B. Riley & Co. has reiterated a Buy rating for Sysorex Global (NASDAQ: SYRX) with a 12-month price target of $2.50 per share.

B. Riley & Co. analysts Josh Nichols, CFA and Mike Crawford highlighted the value of Sysorex’s transition from a Value-added Reseller (VAR) of storage and computing products and services to a provider of high-margin big data analytics, SaaS, and professional services with proprietary products and technologies that help data-driven enterprises improve decision-making and productivity. Nichols and Crawford note, “The company’s near $50MM/yr VAR business provides 700+ enterprise relationships and a revenue foundation, where we believe SYRX can apply its unique blend of proprietary technology to build out high-margin growth businesses in 2016 and generate positive EBITDA and FCF by early 2017.”

Sysorex’s upcoming launch of LightMiner, a big data analytics system using the assets acquired in April 2015, as well as the recent launch of AirPatrol for Healthcare, a unified Real Time Location System (uRTLS) that incorporates multiple equipment tracking technologies into a single platform, were contributing factors for B. Riley’s reiterated Buy rating.

About Market Exclusive

Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

SOURCE: Market Exclusive

ReleaseID: 437658